WO2024025896A3 - Protein kinase c (pkc) theta inhibitor compounds - Google Patents

Protein kinase c (pkc) theta inhibitor compounds Download PDF

Info

Publication number
WO2024025896A3
WO2024025896A3 PCT/US2023/028603 US2023028603W WO2024025896A3 WO 2024025896 A3 WO2024025896 A3 WO 2024025896A3 US 2023028603 W US2023028603 W US 2023028603W WO 2024025896 A3 WO2024025896 A3 WO 2024025896A3
Authority
WO
WIPO (PCT)
Prior art keywords
pkc
protein kinase
inhibitor compounds
theta inhibitor
theta
Prior art date
Application number
PCT/US2023/028603
Other languages
French (fr)
Other versions
WO2024025896A2 (en
Inventor
Andrew Tasker
Hironobu Maezaki
Hans Hofland
William Greenlee
Original Assignee
Evommune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evommune, Inc. filed Critical Evommune, Inc.
Publication of WO2024025896A2 publication Critical patent/WO2024025896A2/en
Publication of WO2024025896A3 publication Critical patent/WO2024025896A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are protein kinase C (PKC) theta inhibitor compounds. Also provided are methods of use of such compounds, as well as pharmaceutical compositions thereof.
PCT/US2023/028603 2022-07-25 2023-07-25 Protein kinase c (pkc) theta inhibitor compounds WO2024025896A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263392058P 2022-07-25 2022-07-25
US63/392,058 2022-07-25

Publications (2)

Publication Number Publication Date
WO2024025896A2 WO2024025896A2 (en) 2024-02-01
WO2024025896A3 true WO2024025896A3 (en) 2024-03-07

Family

ID=89707133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/028603 WO2024025896A2 (en) 2022-07-25 2023-07-25 Protein kinase c (pkc) theta inhibitor compounds

Country Status (1)

Country Link
WO (1) WO2024025896A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069337A1 (en) * 2007-08-15 2009-03-12 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
US7985748B2 (en) * 2005-08-25 2011-07-26 Pharmacopeia Drug Discovery, Inc. ALPHA2C adrenoreceptor agonists
US8093128B2 (en) * 2007-05-25 2012-01-10 Cypress Semiconductor Corporation Integration of non-volatile charge trap memory devices and logic CMOS devices

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985748B2 (en) * 2005-08-25 2011-07-26 Pharmacopeia Drug Discovery, Inc. ALPHA2C adrenoreceptor agonists
US8093128B2 (en) * 2007-05-25 2012-01-10 Cypress Semiconductor Corporation Integration of non-volatile charge trap memory devices and logic CMOS devices
US20090069337A1 (en) * 2007-08-15 2009-03-12 Memory Pharmaceuticals Corporation 3' substituted compounds having 5-ht6 receptor affinity
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubchem 19 August 2012 (2012-08-19), PUBCHEM ANONYMOUS: "6-(1H-indol-5-yl)-N-phenyl-2,3dihydropyrido[3,2-b][1,4]oxazine-4carboxamide", XP093162252, Database accession no. CID58346263 *
PERRY, B. ET AL: "Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 18, no. 16, 15 August 2008 (2008-08-15), Amsterdam NL , pages 4700 - 4704, XP023613453, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2008.06.104 *

Also Published As

Publication number Publication date
WO2024025896A2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
WO2021219091A3 (en) Quinoxalinone derivative as irreversible inhibitor of kras g12c mutant protein
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
EA200701257A1 (en) PYRROPHORASOLES AS A STRONGLY-ACTING KINASE INHIBITORS
CY1112117T1 (en) Hydroxylated and methoxylated cyclopters [D] Pyrimidines as protein kinase inhibitors
MY151455A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
SE0101675D0 (en) Novel composition
WO2019035863A8 (en) Pyruvate kinase activators for use in treating blood disorders
MX2020009234A (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof.
MX2023003443A (en) Alpha protein kinase 1 inhibitors and methods of use.
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
WO2005097087A3 (en) Merged ion channel modulating compounds and uses thereof
EP4249070A3 (en) Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CR20220478A (en) Benzodiazepine derivatives as gaba a gamma1 pams
MX2023011014A (en) Heteroaryl inhibitors of plasma kallikrein.
WO2023212612A3 (en) Certain chemical entities, compositions, and methods
CR20220667A (en) Tetrazole derivatives as trpa1 inhibitors
WO2024025896A3 (en) Protein kinase c (pkc) theta inhibitor compounds
WO2021023888A8 (en) Quinoline derivatives as protein kinase inhibitors
WO2006034390A3 (en) Inhibitors of 15-lipoxygenase
WO2022104153A3 (en) Compounds and methods for treating viral infections
AU2021315475A8 (en) Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
MX2023002288A (en) Protein secretion inhibitors.
WO2022040111A3 (en) Solid state forms of erdafitinib salts and processes for preparation of erdafitinib

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23847269

Country of ref document: EP

Kind code of ref document: A2